pharmaceutical investing Acerus Announces Results of Phase 1 Clinical Trial with a Proprietary Intranasal Formulation of a Tetrahydrocannabinol-Rich Cannabis Oil
pharmaceutical investing Acerus Provides Update on Continuing Commercial and R&D Achievements for NATESTO®
pharmaceutical investing Acerus Announces Expansion of NATESTO® Agreement with medac and the Submission of NATESTO® Dossier in Europe
Locksley Appoints Former U.S. Airforce Major General & General Dynamics IT Executive to Advisory Board
